Baohui Zhu, Ryota Ouda, Paul de Figueiredo, Koichi S Kobayashi
{"title":"ORF6, a repressor of the MHC class I pathway: new molecular target for SARS-CoV-2 drug discovery?","authors":"Baohui Zhu, Ryota Ouda, Paul de Figueiredo, Koichi S Kobayashi","doi":"10.1080/14728222.2023.2248377","DOIUrl":null,"url":null,"abstract":"Department of Immunology, Hokkaido University Graduate School of Medicine, Sapporo, Japan; Christopher S. Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, and Department of Veterinary Pathobiology, University of Missouri, Columbia, MO, USA; Hokkaido University, Institute for Vaccine Research and Development (HU-IVReD), Sapporo, Japan; Department of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, Bryan, TX, USA","PeriodicalId":12185,"journal":{"name":"Expert Opinion on Therapeutic Targets","volume":" ","pages":"639-644"},"PeriodicalIF":4.6000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728222.2023.2248377","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Department of Immunology, Hokkaido University Graduate School of Medicine, Sapporo, Japan; Christopher S. Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, and Department of Veterinary Pathobiology, University of Missouri, Columbia, MO, USA; Hokkaido University, Institute for Vaccine Research and Development (HU-IVReD), Sapporo, Japan; Department of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, Bryan, TX, USA
期刊介绍：
The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials.
The Editors welcome:
Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development.
Articles should not include clinical information including specific drugs and clinical trials.
Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs.
The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
